Treatment of patients with comorbid depression and diabetes with metformin and milnacipran

Peter HofmannUniversity Clinic of Psychiatry, Graz Medical University, Graz, AustriaAbstract: Depression is twice as frequent in patients with diabetes as in the general ­population, and has a negative impact on self-care, adherence to treatment, and the general prognosis of diabetes. Th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Peter Hofmann
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://doaj.org/article/f8cea47e4e3a44ea818d1f29d00ac9b5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f8cea47e4e3a44ea818d1f29d00ac9b5
record_format dspace
spelling oai:doaj.org-article:f8cea47e4e3a44ea818d1f29d00ac9b52021-12-02T03:59:36ZTreatment of patients with comorbid depression and diabetes with metformin and milnacipran1176-63281178-2021https://doaj.org/article/f8cea47e4e3a44ea818d1f29d00ac9b52010-08-01T00:00:00Zhttp://www.dovepress.com/treatment-of-patients-with-comorbid-depression-and-diabetes-with-metfo-a5110https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Peter HofmannUniversity Clinic of Psychiatry, Graz Medical University, Graz, AustriaAbstract: Depression is twice as frequent in patients with diabetes as in the general ­population, and has a negative impact on self-care, adherence to treatment, and the general prognosis of diabetes. This underscores the importance of screening all diabetic patients for depression and, if necessary, treating it with an effective antidepressant drug in parallel with standard diabetes ­treatment. In a recent study, a simple two-question screening tool was used to screen diabetic patients for comorbid depression. The effects of the serotonin and norepinephrine reuptake inhibitor antidepressant, milnacipran, on metabolic parameters and depressive ­symptoms in 64 diabetic patients with comorbid depression detected by this screen were ­studied. Patients received ­milnacipran for 6 months, in addition to standard diabetes treatment with metformin. At the end of the study, 72% of patients had responded to antidepressant treatment (≥50% reduction of baseline Beck Depression Score). The proportion of patients with <8% glycosylated hemoglobin HbA1c (a common indication in diabetes of the need for intensive therapeutic intervention) had decreased significantly from 46.6% at baseline to 6.9%. HbA1c, fasting blood glucose, body mass index, total and low-density lipoprotein cholesterol, and serum triglyceride levels were all significantly decreased in patients with an antidepressant response, but not in patients whose depressive symptoms had not responded to milnacipran.Keywords: depression, diabetes, milnacipran, serotonin, norepinephrine, reuptake inhibitors Peter HofmannDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Supplement 1, Pp 9-15 (2010)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Peter Hofmann
Treatment of patients with comorbid depression and diabetes with metformin and milnacipran
description Peter HofmannUniversity Clinic of Psychiatry, Graz Medical University, Graz, AustriaAbstract: Depression is twice as frequent in patients with diabetes as in the general ­population, and has a negative impact on self-care, adherence to treatment, and the general prognosis of diabetes. This underscores the importance of screening all diabetic patients for depression and, if necessary, treating it with an effective antidepressant drug in parallel with standard diabetes ­treatment. In a recent study, a simple two-question screening tool was used to screen diabetic patients for comorbid depression. The effects of the serotonin and norepinephrine reuptake inhibitor antidepressant, milnacipran, on metabolic parameters and depressive ­symptoms in 64 diabetic patients with comorbid depression detected by this screen were ­studied. Patients received ­milnacipran for 6 months, in addition to standard diabetes treatment with metformin. At the end of the study, 72% of patients had responded to antidepressant treatment (≥50% reduction of baseline Beck Depression Score). The proportion of patients with <8% glycosylated hemoglobin HbA1c (a common indication in diabetes of the need for intensive therapeutic intervention) had decreased significantly from 46.6% at baseline to 6.9%. HbA1c, fasting blood glucose, body mass index, total and low-density lipoprotein cholesterol, and serum triglyceride levels were all significantly decreased in patients with an antidepressant response, but not in patients whose depressive symptoms had not responded to milnacipran.Keywords: depression, diabetes, milnacipran, serotonin, norepinephrine, reuptake inhibitors
format article
author Peter Hofmann
author_facet Peter Hofmann
author_sort Peter Hofmann
title Treatment of patients with comorbid depression and diabetes with metformin and milnacipran
title_short Treatment of patients with comorbid depression and diabetes with metformin and milnacipran
title_full Treatment of patients with comorbid depression and diabetes with metformin and milnacipran
title_fullStr Treatment of patients with comorbid depression and diabetes with metformin and milnacipran
title_full_unstemmed Treatment of patients with comorbid depression and diabetes with metformin and milnacipran
title_sort treatment of patients with comorbid depression and diabetes with metformin and milnacipran
publisher Dove Medical Press
publishDate 2010
url https://doaj.org/article/f8cea47e4e3a44ea818d1f29d00ac9b5
work_keys_str_mv AT peterhofmann treatmentofpatientswithcomorbiddepressionanddiabeteswithmetforminandmilnacipran
_version_ 1718401528818040832